このエントリーをはてなブックマークに追加
ID 13222
Eprint ID
13222
FullText URL
Thumnail 119_273.pdf 750 KB
Title Alternative
I The diagnosis of and therapy for breast cancer
Author
Keywords
乳がん
診断
手術
薬物療法
Note
特集 がんの標準的治療
Published Date
2008-01-04
Publication Title
岡山医学会雑誌
Publication Title Alternative
Journal of Okayama Medical Association
Volume
volume119
Issue
issue3
Publisher
岡山医学会
Publisher Alternative
Okayama Medical Association
Start Page
273
End Page
283
ISSN
00301558
NCID
AN00032489
Content Type
Journal Article
Related Url
http://www.okayama-u.ac.jp/user/oma/
References
1) Kitagawa T, Tsukuma H, et al. : Prediction of cancer incidence in Japan ; in Cancer Statistics-1999, Tominaga S, et al. eds, Shinohara Shuppan, Tokyo (1999) pp 159-170.
2) Morrow M, Wong S, Venta L : The evaluation of breast masses in women younger than forty years of age. Surgery (1998) 124 (4), 634-640.
3) Hindle WH : Breast mass evaluation. Clin Obstet Gynecol (2002) 45 (3), 750-757.
4) Hindle WH, Davis L, Wright D : Clinical value of mammography for symptomatic women 35 years of age and younger. Am J Obstet Gynecol (1999) 80 (6 Pt 1), 1484-1490.
5) Harris VJ, Jackson VP : Indications for breast imaging in women under age 35 years. Radiology (1989) 172 (2), 445-448.
6) Brand IR, Sapherson DA, Brown TS : Breast imaging in women under 35 with symptomatic breast disease. Br J Radiol (1993) 66 (785), 394-397.
7) Bassett LW, Ysrael M, Gold RH, et al. : Usefulness of mammography and sonography in women less than 35 years of age. Radiology (1991) 180 (3), 831-835.
8) Ball CG, Butchart M, MacFarlane JK : Effect on biopsy technique of the breast imaging reporting and data system (BI-RADS) for nonpalpable mammographic abnormalities. Can J Surg (2002) 45 (4), 259-263.
9) Orel SG, Kay N, Reynolds C, et al. : BI-RADS categorization as a predictor of malignancy. Radiology (1999) 211 (3), 845-850.
10) Flobbe K, Bosch AM, Kessels AG, et al. : The additional diagnostic value of ultrasonography in the diagnosis of breast cancer. Arch Intern Med (2003) 163 (10), 1194-1199.
11) Soo MS, Rosen EL, Baker JA, et al. : Negative predictive value of sonography with mammography in patients with palpable breast lesions. Am J Roentgenol (2001) 177 (5), 1167-1170.
12) Zonderland HM, Coerkamp EG, Hermans J, et al. : Diagnosis of breast cancer : contribution of US as an adjunct to mammography. Radiology (1999) 213 (2), 413-422.
13) Ciatto S, Cariaggi P, Bulgaresi P : The value of routine cytologic examination of breast cyst fluids. Acta Cytol (1987) 31 (3), 301-304.
14) Giard RW, Hermans J : The value of aspiration cytologic examination of the breast. A statistical review of the medical literature. Cancer (1992) 69 (8), 2104-2110.
15) Layfield LJ, Glasgow BJ, Cramer H : Fine-needle aspiration in the management of breast masses. Pathol Annu (1989) 24 (2), 23-62.
16) Nakayama K, Abe R, Kimijima I, et al. : Evaluation of aspiration biopsy cytology and combined preoperative tests in the diagnosis of breast cancer. Surg Today (1995) 25 (5), 404-408.
17) Hatada T, Ishii H, Ichii S, et al. : Diagnostic value of ultrasound-guided fine-needle aspiration biopsy, core-needle biopsy, and evaluation of combined use in the diagnosis of breast lesions. J Am Coll Surg (2000) 190 (3), 299-303.
18) Ibrahim AE, Bateman AC, Theaker JM, et al. : The role and histological classification of needle core biopsy in comparison with fine needle aspiration cytology in the preoperative assessment of impalpable breast lesions. J Clin Pathol (2001) 54 (2), 121-125.
19) Diaz LK, Wiley EL, Venta LA : Are malignant cells displaced by large-gauge needle core biopsy of the breast? AJR Am J Roentgenol (1999) 173 (5), 1303-1313.
20) Kettritz U, Rotter K, Schreer I, et al. : Stereotactic vacuum-assisted breast biopsy in 2874 patients : a multicenter study. Cancer (2004) 100 (2), 245-251.
21) Helbich TH, Matzek W, Fuchsjäger MH : Stereotactic and ultrasound-guided breast biopsy. Eur Radiol (2004) 14 (3), 383-393.
22) Fisher B, Ravdin RG, Ausman RK, et al. : Surgical adjuvant chemotherapy in cancer of the breast : results of a decade of cooperative investigation. Ann Surg (1968) 168 (3), 337-356.
23) Fisher B, Redmond C, Fisher ER, et al. : Systemic adjuvant therapy in treatment of primary operable breast cancer : National Surgical Adjuvant Breast and Bowel Project experience. NCI Monogr (1986) 1, 35-43.
24) Patey DH, Dyson WH : The prognosis of carcinoma of the breast in relation to the type of operation performed. Br J Cancer (1948) 2, 7-13.
25) Auchincloss H : Significance of location and number of axillary metastases in carcinoma of the breast : A justification for a conservative operation. Ann Surg (1963) 158, 37-46.
26) Turner L, Swindell R, Bell WGT, et al. : Radical versus modified radical mastectomy for breast cancer. Ann Royal Coll Surg Engl (1981) 63, 239-243.
27) Maddox WA, Carpenter JT, Laws H, et al. : A randomized prospective trial of radical (Halsted) mastectomy versus modified radical mastectomy in 311 breast cancer patients. Ann Surg (1983) 198, 207-212.
28) National Cancer Institute : The treatment of primary breast cancer : Management of local disease. NIH Consensus Development Conference Summary (1979) 2, 1-3.
29) National Institutes of Health Consensus Development Panel : Consensus statement ; treatment of early stage breast cancer. J Natl Cancer Inst Monogr (1992) 11, 1-5.
30) Veronesi U, Cascinelli N, Mariani L, et al. : Twenty-year follow-up of a randomized study comparing breast-conserving surgery with radical mastectomy for early breast cancer. N Engl J Med (2002) 347, 1227-1232.
31) Fisher B, Anderson S, Redmond CK, et al. : Reanalysis and results after 12 years of follow-up in a randomized clinical trial comparing total mastectomy with lumpectomy with or without irradiation in the treatment of breast cancer. N Engl J Med (1995) 333, 1456-1461.
32) Fisher B, Jeong JH, Anderson S, et al. : Twenty-five-year follow up of randomized trial comparing radical mastectomy, total mastectomy, and total mastectomy followed by irradiation. N Engl J Med (2002) 347 (8), 567-575.
33) Krag D, Weaver D, Ashikaga T, et al. : The sentinel node in breast cancer. A multicenter validation study. N Engl J Med (1998) 339, 941-946.
34) Hutchins LF, Green SJ, Ravdin PM, et al. : Randomized, controlled trial of cyclophosphamide, methotrexate, and fluorouracil versus cyclophosphamide, doxorubicin, and fluorouracil with and without tamoxifen for high-risk, node-negative breast cancer : treatment results of Intergroup Protocol INT-0102. J Clin Oncol (2005) 23 (33), 8313-8321.
35) Henderson IC, Berry DA, Demetri GD, et al. : Improved outcomes from adding sequential paclitaxel but not from escalating doxorubicin dose in an adjuvant chemotherapy regimen for patients with node-positive primary breast cancer. J Clin Oncol (2003) 21 (6), 976-983.
36) Mamounas EP, Bryant J, Lembersky BC, Fisher B, Atkins JN, Fehrenbacher L, et al. : Paclitaxel following doxorubicin/cyclophosphamide as adjuvant chemotherapy for node-positive breast cancer : results from NSABP B-28. Proc Am Soc Clin Oncol (2003) 22, 4.
37) Buzdar AU, Singletary SE, Valero V, et al. : Evaluation of paclitaxel in adjuvant chemotherapy for patients with operable breast cancer : preliminary data of a prospective randomized trial. Clin Cancer Res (2002) 8, 1073-1079.
38) Citron ML, Berry DA, Cirrincione C, et al. : Randomized trial of dose-dense versus conventionally scheduled and sequential versus concurrent combination chemotherapy as postoperative adjuvant treatment of node-positive primary breast cancer : first report of Intergroup Trial C9741/Cancer and Leukemia Group B Trial 9741. J Clin Oncol (2003) 21 (8), 1431-1439.
39) Early Breast Cancer Trialists' Collaborative Group : Tamoxifen for early breast cancer : an overview of the randomized trials. Lancet (1998) 351, 1451-1467.
40) ATAC Trialists' Group : Results of the ATAC (Arimidex, Tamoxifen, Alone or in Combination) trial after completion of 5 years adjuvant treatment for breast cancer. Lancet (2005) 365 (9453), 60-62.
41) Coombes RC, Hall E, Gibson LJ, et al. : Intergroup Exemestane Study : A randomized trial of exemestane after two to three years of tamoxifen therapy in postmenopausal women with primary breast cancer. N Engl J Med (2004) 350 (11), 1081-1092.
42) Herceptin Adjuvant (HERA) Trial Study Team : Trastuzumab after adjuvant chemotherapy in HER2-positive breast cancer. N Engl J Med (2005) 353 (16), 1659-1672.
43) HERA study team : 2-year follow-up of trastuzumab after adjuvant chemotherapy in HER2-positive breast cancer : a randomised controlled trial. Lancet (2007) 369 (9555), 29-36.
language
日本語
OAI-PMH Set
岡山大学
Copyright Holders
岡山医学会
File Version
publisher
Refereed
True
DOI
Sort Key
9
Eprints Journal Name
joma